Best Contracting Services Honored as Regional Contractor of the Year by Tremco Incorporated at the 2025 IRE
Best Contracting Services, a leading provider of roofing, waterproofing, and building envelope solutions, has been named Regional Contractor of the Year by Tremco Incorporated at the 2025 International Roofing Expo (IRE) at The Alamo in San Antonio, Texas.
This prestigious award recognizes Best Contracting Services' commitment to excellence, innovation, and outstanding performance in the commercial roofing industry. The award represents the second industry commendation presented to Best Contracting Services during this year's IRE.
'We are honored to receive this recognition from Tremco Incorporated,' said Sean Taba, CEO of Best Contracting Services. 'At Best Contracting Services, we take immense pride in delivering top-tier roofing and weatherproofing solutions that stand the test of time. This award is a testament to the dedication and expertise of our entire team, as well as our strong partnership with Tremco in delivering high-performance solutions to our clients.'
Best Contracting Services has built a strong reputation for excellence, reliability, and craftsmanship in the commercial roofing industry. With decades of experience, the company specializes in roofing, waterproofing, and building envelope solutions for a diverse range of projects, including government facilities, commercial properties, and industrial complexes.
The IRE serves as a key gathering for industry leaders, showcasing the latest trends, innovations, and best practices in the roofing and waterproofing sector. Winning the Regional Contractor of the Year Award at such a prestigious event highlights Best Contracting Services' leadership and ongoing contributions to the industry.
About Best Contracting Services:
Best Contracting Services is a premier commercial roofing and waterproofing company based in Gardena, California. With decades of experience, the company specializes in providing cutting-edge solutions to meet the needs of diverse clients across various industries. Known for its commitment to quality, safety, and sustainability, Best Contracting Services continues to set new benchmarks in the construction sector.
3106503681
SOURCE: Best Contracting Services
Copyright Business Wire 2025.
PUB: 02/21/2025 11:00 AM/DISC: 02/21/2025 11:03 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15-05-2025
- Yahoo
EU Wants More In U.S. Trade Deal Than U.K. Or China Got
The European Union wants a trade deal with the U.S. that sees a larger reduction in tariffs than negotiations with the U.K. and China have so far yielded, officials from the bloc said Thursday. President Trump has imposed a series of tariffs that affect Europe's makers of automobiles, steel and aluminum. On April 2, he announced a sharp rise in tariffs on all imports from Europe, but a week later reduced the increase to 10% for 90 days to allow for negotiations. Bags of Cash From Drug Cartels Flood Teller Windows at U.S. Banks Warren Buffett Reveals He Stepped Down After Finally Feeling His Age Dick's Sporting Goods to Buy Foot Locker for $2.4 Billion Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals 401(k) Giant to Allow Private Markets Investments in Its Retirement Portfolios Last week, the U.S. and the U.K. announced an agreement that left 10% 'baseline' tariffs in place on a wide range of British exports to the world's largest economy. In an agreement announced Monday, the U.S. and China agreed to dial back some recent tariff hikes for 90 days, but left duties above the levels that prevailed before Trump took office. 'I don't think that's the level of ambition Europe would be happy with,' said Michal Baranowski, Poland's deputy economy minister, who is chairing a meeting of EU trade officials in Brussels. Sweden's trade minister said the EU should retaliate with higher tariffs on imports from the U.S. if a 10% baseline tariff were to be the final offer from the Trump administration. 'It's far away from good for trade,' said Benjamin Dousa. 'If that's what's waiting for Europe, the U.S. can expect countermeasures from our side.' The Polish official noted that the EU is on day 37 of the 90-day pause, and 'has time' to secure the broad deal that it seeks. 'We don't need a quick deal, we need a good deal,' Baranowski said. 'So does America. We have time.' Officials said negotiations between the European Union and the U.S. are making progress. 'We are seeing some elements of optimism because we are seeing elements of de-escalation on the U.S. side,' said Baranowski. 'That's a good sign that negotiations with the EU are speeding up.' Also speaking to reporters ahead of the meeting, EU Trade Commissioner Maros Sefcovic said he had a 'constructive call' with U.S. Commerce Secretary Howard Lutnick on Wednesday. 'Our aim is to resolve the immediate challenges but also to lay the groundwork for deeper cooperation,' Sefcovic said. But there is the potential for fresh tension. The U.S. has initiated an investigation of the trade in pharmaceuticals under Section 232 of the Trade Expansion Act of 1962, which allows the president to impose tariffs on goods deemed essential for national security. Simon Harris, deputy prime minister of Ireland, said higher tariffs would harm both the U.S. and the EU. A number of large U.S. pharmaceutical companies have big factories in Ireland that make drugs which are shipped back home. 'The idea that Ireland or the EU poses any sort of security threat to the U.S. is absurd,' Harris said. Write to Paul Hannon at The Paramount Executive Caught Between Trump, His Boss and Angry CBS Staffers Why UnitedHealth's Blowup May Be More Isolated Than Investors Think Cassie Ventura Says Sean 'Diddy' Combs Used Blackmail Threats, Violence to Control Her Warner's Streaming Service Has New Name: Its Old One. Meet 'HBO Max.' CoreWeave CEO Says Increased Spending to Meet Demand Will Squeeze Earnings
Yahoo
25-04-2025
- Yahoo
Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting
Omny-IRE data demonstrated the investigational OMNYPULSE™ Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durability at three months, with promising safety outcomes1 Additional data presented from VARIPURE registry2 and Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter3 pre-clinical study underscore safety and real-world efficiency across Johnson & Johnson MedTech's expanding pulsed field ablation portfolio IRVINE, Calif., April 25, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced positive, initial 3-month results from the Omny-IRE study, evaluating the investigational OMNYPULSE™ Platform in patients with paroxysmal atrial fibrillation (PAF). The data, unveiled as a late breaking presentation at the 2025 Heart Rhythm Society (HRS) annual meeting, demonstrated the potential for both high acute effectivenessi and a promising safety profile: 100% acute PVI with durable isolation in 84.5% of pulmonary veins at 3-month remapping and a 3.0% primary adverse event rate, with only 0.7% being potentially catheter related.1 The data has been simultaneously published in JACC Clin Electrophysiology. Omny-IRE is a 12-month prospective, multi-center, non-randomized clinical trial that evaluates the safety and effectiveness of the OMNYPULSE™ Platform for the mapping and treatment of symptomatic PAF during standard ablation The OMNYPULSE™ Platform consists of the OMNYPULSE™ Catheter, a novel focal pulsed field ablation (PFA) catheter, and the TRUPULSE™ Generator, and is fully integrated with the CARTO™ 3 System. The OMNYPULSE™ Catheter is the first large-tip, 12 mm focal catheter with contact force sensing and a TRUEref™ reference electrode to reduce the impact of far-field unipolar signals. The TRUPULSE™ Generator provides a bipolar, biphasic pulse application to the catheter's twelve electrodes. With the CARTO™ 3 System software used in the study, clinicians were able to obtain a Pulsed Field (PF) Index value for each ablation, which is a calculation using the real-time contact force feedback combined with the number of pulsed field applications.5 As an integrated platform, OMNYPULSE™ brings together mapping precision, energy delivery, and real-time feedback into a single ecosystem—streamlining workflows and helping electrophysiologists deliver more consistent outcomes.1 "The 3-month data provide encouraging early evidence of the OMNYPULSE™ Platform," said Mattias Duytschaever M.D., Ph.D., Department of Cardiology, Electrophysiology Section, AZ Sint-Jan Hospital, Brugge, "What's most compelling is the combination of 100% acute and strong remap success1 with a low rate of safety events. These results reinforce the potential of OMNYPULSE and its integration with the CARTO™ 3 System to deliver reproducible, durable outcomes for patients with paroxysmal AFib." In addition, data from the VARIPURE study are being shared at the HRS Annual Meeting, evaluating the real-world safety and operator learning curve associated with the use of the VARIPULSE™ Platform PVI procedures for atrial fibrillation. Conducted across 13 European sites, the prospective, post-market study included 247 patients and 40 operators with varying levels of experience, including first-time users. Notably, no serious adverse events were reported, and no complications were linked to the platform, including zero neurovascular events or coronary spasms. Among a subset of 115 patients treated by operators performing their first 10 VARIPULSE™ cases, results showed no measurable learning curve beyond a modest reduction in idle time between ablations, underscoring the efficiency and ease of adopting this innovative technology.2 VARIPURE is an ongoing registry, with over 600 patients enrolled to date. "The VARIPULSE™ Platform has both a strong safety profile and is highly accessible to new users, enabling safe and consistent outcomes from the very first case. As adoption of PFA expands, I believe VARIPULSE™ can play a key role in broadening access to safe and streamlined ablation procedures," said Francis Bessière M.D., Ph.D., Cardiac Electrophysiology Department, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Additional data presented at HRS by Dr. Hiroshi Nakagawa include new preclinical validation of a PF Index from the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter, leveraging data from lesions created in a swine beating heart model. The analysis confirmed that lesion depth, which is crucial for effective treatment, correlates strongly with the number of PFA pulses and contact force using a logarithmic PF Index—accurately predicting lesion depth within ±1 mm in 92% of cases and ±1.5 mm in all cases. These findings reinforce the reliability of the pulse dosing protocol and underline the PF Index's value as a practical tool for guiding ablation. The index is specifically optimized to support durable lesion formation, offering physicians confidence in its outputs and enabling them to make informed, real-time decisions with a high degree of procedural predictability and clinical precision.3 These multiplatform findings advance the clinical and technical validation of Johnson & Johnson MedTech's PFA portfolio across focal, regional and dual energy catheter designs—each leveraging CARTO™ 3 System integration and real-time lesion feedback. These latest data are part of Johnson & Johnson MedTech's commitment to advancing understanding of PFA, including the recently announced 12-month results from the SmartfIRE clinical trial presented in March 2025. "Our PFA portfolio is built around what matters most to physicians—durability, control, safety and efficiency," said Jennifer Currin, Ph.D., Vice President, Scientific Affairs, Johnson & Johnson MedTech. "The Omny-IRE, VARIPURE, and Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter data demonstrate our commitment to delivering safe, effective, and reliable PFA tools." Additional information on Johnson & Johnson's data presented at HRS can be found here. About The OMNYPULSE™ Platform The investigational OMNYPULSE™ Platform uses pulsed electrical field energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation. The platform includes the TRUPULSE™ multichannel generator and multi-electrode OMNYPULSE™ Catheter used in conjunction with the CARTO™ 3 System with the VISITAG SURPOINT™ Module PF Index to provide electroanatomical maps, contact force sensing, PF Index values and catheter localization information for ablations for the treatment of paroxysmal atrial fibrillation. The OMNYPULSE™ Platform is not currently approved in any region of the world. About The Omny-IRE Study Omny-IRE is a pivotal, prospective, multi-center, non-randomized study in Europe and Canada to demonstrate the safety and effectiveness of Johnson & Johnson MedTech's OMNYPULSE™ Platform, the principal components of which are the OMNYPULSE™ Catheter and the TRUPULSE™ Generator. The study is evaluating the system for the treatment of symptomatic paroxysmal atrial fibrillation during standard electrophysiology mapping and ablation procedures while also evaluating the incidence of primary adverse events within seven days post-procedure. About the VARIPULSE™ PlatformThe VARIPULSE™ Platform consists of the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Software. The VARIPULSE Catheter is a variable-loop circular catheter (VLCC) used for pulsed field ablation (PFA) in atrial fibrillation treatment, particularly for pulmonary vein isolation, and allows for adjustment of the loop size to conform to different patient anatomies. About the Dual Energy THERMOCOOL SMARTTOUCH™ SF CatheterThe Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform consists of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter – an irrigated, contact-force sensing catheter – and the TRUPULSE™ Generator, providing both RF and PF energy to the catheter through the toggling of the two energy sources on the generator monitor.6 The catheter and the generator are fully integrated with the CARTO™ 3 System, enabling advanced 3D mapping visualization with integrated ultrasound during ablation procedures.v The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is the first dual energy PFA / RF ablation catheter integrated with a PF and RF tag index. The Catheter received European CE Mark in December 2024; it is investigational in the United States. Cardiovascular Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circular restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit and connect on LinkedIn and X, formerly Twitter. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at Biosense Webster, Inc. is part of Johnson & Johnson MedTech. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the OMNYPULSE™ Platform clinical trials, VARIPULSE™ Platform, CARTO™ 3 System, and Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of healthcare products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Neither Biosense Webster, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. © Johnson & Johnson and its affiliates 2025. All rights reserved. US_ELP_NAVI_399689i Acute efficacy was defined to be adenosine/isoproterenol-proof PVI at the end of the procedure and had a 90% performance goal. ii 12-month results to be published once available (or upon study completion) iii AZ Sint-Jan Hospital entered into a clinical trial agreement with Biosense Webster, Inc., part of Johnson & Johnson MedTech for their participation in the Omny-IRE Study. Dr. Duytschaever served as a study coinvestigator. Dr. Duytschaever serves as a consultant for Johnson & Johnson but was not compensated for this announcement. iv VARIPURE (VARIPULSE™ Catheter data exchange Platform powered by SECURE) is a SECURE substudy. Hospices Civils de Lyon - Bron entered into a clinical trial agreement with Biosense Webster, Inc., part of Johnson & Johnson MedTech for their participation in the SECURE Study. Dr. Bessière served as a site principal investigator. Dr. Bessière serves as a consultant for Johnson & Johnson but was not compensated for this announcement. v Results reported after 9 months for patients with paroxysmal AFib who had failed 1 antiarrhythmic medication in randomized trial. 1 Duytschaever M, Grimaldi M, De Potter T, et al. Safety, efficacy and PVI durability of a contact force-sensing large-tip focal pulsed field ablation catheter integrated with 3D mapping to treat paroxysmal atrial fibrillation: first-in-human Omny-IRE 3-month results. Presented at HRS 2025; April 25, 2025; San Diego, CA. 2 Bessière F, Kronborg MB, Sommer P, et al. Evaluating Safety Profile and Learning Curve With a Pulsed Field Ablation Variable Loop Circular Catheter in Procedures for AF: Observations From a Prospective, Multicenter, Postmarket Clinical Trial. Presented at HRS 2025; April 27, 2025; San Diego, CA. 3 Nakagawa H, Farshchi S, Maffre J, et al. Predicting Lesion Depth During Pulsed Field Ablation: Prospective Validation of a Novel Ablation Index Based on Contact Force and Number of Applications in a Swine Beating Heart Model. Presented at HRS 2025; April 24, 2025; San Diego, CA. 4 A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator (Omny-IRE). Accessed April 8, 2025. 5 Biosense Webster. (2023). OMNYPULSE™ Bi-Directional Catheter IFU. 6 De Potter T, Scherr D, Pürerfellner H, et al. Safety, effectiveness, and healthcare benefits of a dual energy focal ablation technology to treat paroxysmal atrial fibrillation: SmartfIRE 12-month results. Presented at EHRA 2025; March 31, 2025; Vienna, Austria. Pending formal publication. Media Contacts:Lindsey Diaz-MacInnisldiazmac@ Kristina KauffmanKkauffm4@ Investor Relations:Tracy Menkowskiinvestor-relations@ View original content to download multimedia: SOURCE Johnson & Johnson MedTech Sign in to access your portfolio
Associated Press
09-04-2025
- Associated Press
PGW Auto Glass Relocates Global Headquarters
PGW Auto Glass is excited to announce the relocation of its global headquarters to 2000 Westinghouse Dr. Suite 301, Cranberry Township. This new facility doubles the company's existing corporate square footage and will facilitate greater teamwork, collaboration and innovation among staff with additional amenities. 'We are pleased to announce the relocation of our global headquarters, which will enhance our operations and ability to better serve our customers,' said Todd Fencak, CEO of PGW Auto Glass. 'The new space offers fantastic opportunities for our employees, including gym memberships, walking trails and restaurants. This move allows us to continue our growth journey while providing our top-performing employees with a productive and inviting place to work.' PGW Auto Glass also provides a cost-effective, comprehensive business technology solution, Everything Autoglass, with a suite of features designed to help retail glass installers succeed ( PGW Auto Glass is a portfolio company of One Equity Partners, a leading middle market private equity firm with approximately $10 billion in assets under management focused on transformative combinations within the industrial, healthcare, and technology sectors in North America and Europe. About PGW Auto Glass PGW Auto Glass ( is a leading distributor of automotive replacement glass, specialty parts, shop accessories and business technology solutions in North America, with more than 150 distribution branches throughout the U.S. and Canada. Offering same-day and overnight deliveries, PGW Auto Glass serves OEM dealerships, collision repair shops and automotive glass installers. PGW Auto Glass also provides a cost-effective, comprehensive business technology solution, with a suite of features designed to help retail glass installers succeed. PGW Auto Glass is a portfolio company of One Equity Partners, a leading middle market private equity firm with approximately $10 billion in assets under management focused on transformative combinations within the industrial, healthcare and technology sectors in North America and Europe. Kirsten Brundahl SOURCE: PGW Auto Glass Copyright Business Wire 2025. PUB: 04/09/2025 10:08 AM/DISC: 04/09/2025 10:09 AM
